SCHEMBL30748867

SCHEMBL30748867

O=C(O)c1nccc(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.52
AURKB Q96GD4 3/20 0.52
MAPK8 P45983 4/20 0.51
SCN9A Q15858 2/20 0.49
KCNH2 Q12809 1/20 0.49
SCN5A Q14524 1/20 0.47
ERBB2 P04626 1/20 0.47
PLK1 P53350 1/20 0.46
KDR P35968 3/20 0.46
PIN1 Q13526 1/20 0.45
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 2/20 0.45
RAB9A P51151 2/20 0.45
CHEK1 O14757 1/20 0.45
IKBKB O14920 1/20 0.45
PDPK1 O15530 1/20 0.45
CHEK2 O96017 1/20 0.45
PRKCG P05129 1/20 0.45
CDK1 P06493 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748839 0.89 SCN9A (0.50) AURKAAURKBMAPK8SCN9AKCNH2
SCHEMBL31691345 0.88 ROCK1 (0.51) AURKAAURKBMAPK8SCN9AKCNH2
SCHEMBL3236170 0.87 AURKA (0.61) AURKAAURKBMAPK8KDRNPC1
SCHEMBL15522350 0.78 SCN9A (0.59) AURKASCN9AKCNH2SCN5AERBB2
SCHEMBL30748744 0.78 ERBB2 (0.50) AURKAAURKBMAPK8SCN9AKCNH2
SCHEMBL30748746 0.75 ABCG2 (0.51) AURKASCN9AKCNH2SCN5AERBB2
SCHEMBL30748940 0.75 SCN9A (0.49) AURKAAURKBMAPK8SCN9AKCNH2
SCHEMBL29448928 0.75 AURKA (0.60) AURKAAURKBMAPK8NPC1MAPT
SCHEMBL25884869 0.75 AURKA (0.56) AURKAAURKBMAPK8KDRNPC1
SCHEMBL23337307 0.74 FFAR1 (0.45) MAPK8KDRMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT AURKA 2457/4885AURKB 1989/4885MAPK8 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.